每次減肥都失敗？
美食當前永遠忍唔到口？
醫學界公認最強效瘦瘦筆！
Saxenda秀身達瘦身筆 與 Mounjaro滿健樂瘦身筆
助你增加飽腹感、減少食慾、延緩胃排空，從而幫助減重，被證實能夠有效減輕體重並減少體重反彈風險的減肥筆。
Always Failing at Weight Loss?
Can’t Resist Delicious Food?
Introducing the most effective weight loss pens recognized by the medical community! Saxenda and Mounjaro are designed to help you increase feelings of fullness, reduce appetite, and delay gastric emptying, thereby assisting in weight loss. They have been proven to effectively reduce weight and minimize the risk of weight regain.
Saxenda秀身達新一代減肥針
飢餓感down+飽腹感up=減少進食
Saxenda秀身達減肥筆由歐洲製造的是處方針劑，它的活性成分利骨酐（liraglutide）通過模擬體內自然產生的激素 GLP-1，獲美國FDA歐盟EMA藥物管理局認可。不僅可顯著改善肥胖相關合併症，還可達至自然瘦身效果！專門為針對全身減肥而設計的減肥針，屬於與天然荷爾蒙GLP-1成分相似高達97%。GLP-1可以幫助體內延緩胃部排空。一但食物停留在胃部的時間拉長，就會增加飽足感，抑制飢餓感，促成控制體重的效果。
Saxenda瘦瘦筆適合哪些族群：
- BMI ≥ 30kg/m2的成年人
- BMI ≥ 27kg/m2 至 < 30kg/m2的成年人，並至少有一個肥胖症的合併症，如高血壓、前期糖尿病、二型糖尿病、阻塞怛睡眠窒息症或血脂異常
- 都市生活沒空做運動人士
- 食量大、愛吃零食及宵夜人士
Feeling less hungry + feeling fuller = Reduced food intake
Saxenda is a prescription injection manufactured in Europe. Its active ingredient, liraglutide, mimics the naturally occurring hormone GLP-1 in the body, and it is approved by the FDA in the U.S. and the EMA in Europe. It not only significantly improves obesity-related complications but also achieves natural weight loss results! This weight loss injection is specifically designed for overall body weight reduction and is composed of ingredients similar to the natural hormone GLP-1 by as much as 97%. GLP-1 helps delay gastric emptying, which increases feelings of fullness, suppresses hunger, and promotes effective weight control.
Who is Saxenda Suitable For:
- Adults with a BMI of ≥ 30 kg/m²
- Adults with a BMI of ≥ 27 kg/m² and < 30 kg/m², who also have at least one obesity-related complication, such as hypertension, prediabetes, type 2 diabetes, obstructive sleep apnea, or dyslipidemia
- Individuals with busy urban lifestyles who have no time for exercise
- Those who have a large appetite and enjoy snacks and late-night meals
全球首個雙重腸泌素瘦瘦筆
GLP-1和GIP受體促效劑
Mounjaro滿健樂減肥筆是美國禮來藥廠(Eli Lilly and Company)最新研發的減重筆，目前已被美國FDA核准用於二型糖尿病患者，並在歐美區取得減重適應症。
Mounjaro滿健樂瘦身筆的主要成分為Tirzepatide，這個成分跟以往瘦瘦筆中的成分最大的不同點在於，它是目前全球「首個」雙重腸泌素GLP-1和GIP受體促效劑，除了作用在上述所說的GLP-1受體外，也會作用在GIP受體。雙重機制有更強的優勢：包括減緩胃排空、增加飽足感、促進胰島素分泌，同時抑制升糖素，幫助降低血糖，亦有控制食慾、減少熱量攝取，並改善胰島素敏感度等功效。
Mounjaro減肥筆適合哪些族群：
- 用於治療成人第 2 型糖尿病，透過降低高血糖水平來控制血糖。
- 用於減重和維持體重，適用於以下情況：
- BMI≥30 kg/m²（肥胖）的成人。
- BMI≥27 kg/m² 但<30 kg/m²（過重）且有體重相關健康問題的成人，如糖尿病前期、2 型糖尿病、高血壓、血脂異常、睡眠呼吸中止症等。
The World’s First Dual Incretin Weight Loss Pen:
GLP-1 and GIP Receptor Agonist
Mounjaro is the latest weight loss pen developed by Eli Lilly and Company, which has been approved by the FDA for use in patients with type 2 diabetes and has received weight loss indications in Europe and North America.
The main ingredient in Mounjaro is Tirzepatide, which is distinct from ingredients in previous weight loss pens because it is the world’s first dual incretin GLP-1 and GIP receptor agonist. In addition to acting on the GLP-1 receptor, it also targets the GIP receptor. This dual mechanism offers significant advantages, including: Slowing gastric emptying, increasing feelings of fullness, helping to lower blood sugar levels, controlling appetite, reducing calorie intake and improving insulin sensitivity.
Who is Mounjaro Suitable For:
- Used to treat adults with type 2 diabetes by lowering high blood sugar levels to help control blood glucose.
- Used for weight loss and weight maintenance in the following situations:
- Adults with a BMI of ≥ 30 kg/m² (obesity).
- Adults with a BMI of ≥ 27 kg/m² but < 30 kg/m² (overweight) who have weight-related health issues, such as prediabetes, type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea.
Mounjaro 滿健樂 vs Saxenda 秀身達
兩者應如何選擇？
兩者都是用於治療肥胖的藥物，但它們的作用機制和效果有所不同。 Mounjaro滿健樂瘦身筆是一種雙重作用藥物，結合了GLP-1 和GIP 受體促效劑，而Saxenda秀身達減肥筆則是一種單一作用的GLP-1 受體促效劑。
主要區別如下：
作用機制：
Mounjaro瘦身筆透過刺激GLP-1 和GIP 受體來調節血糖和食慾，而Saxenda瘦身筆則主要透過刺激GLP-1 受體來抑制食慾。
減重效果：
Mounjaro瘦身筆的減重效果通常較Saxenda瘦身筆顯著，研究顯示Mounjaro瘦身筆可能能達到15-22% 的體重減輕，而Saxenda瘦身筆的減重效果則較為溫和。
給藥頻率：
Mounjaro瘦身筆每週注射一次，而Saxenda瘦身筆則需要每日注射。
適用對象：
Mounjaro瘦身筆主要適用於BMI ≥ 30 或BMI ≥ 27 且伴有肥胖相關疾病的第二型糖尿病患者，而Saxenda瘦身筆則適用於BMI ≥ 30 或BMI ≥ 27 且伴有肥胖相關疾病（如高血壓、糖尿病）的患者。
血糖控制：
Mounjaro瘦身筆對於第二型糖尿病患者的血糖控制效果較佳。
總結：
Mounjaro瘦身筆和Saxenda瘦身筆都是有效的減重藥物，但Mounjaro瘦身筆在減重效果和給藥頻率上可能更具優勢，尤其對第二型糖尿病患者。 然而，選擇哪種藥物仍需根據個人情況和醫師建議而定。
Choosing Between Mounjaro and Saxenda
Both are medications used for treating obesity, but their mechanisms of action and effects differ. Mounjaro is a dual-action medication combining GLP-1 and GIP receptor agonists, while Saxenda is a single-action GLP-1 receptor agonist.
Mechanism of Action:
Mounjaro regulates blood sugar and appetite by stimulating both GLP-1 and GIP receptors. Saxenda primarily suppresses appetite by stimulating GLP-1 receptors.
Weight Loss Effects:
Mounjaro typically shows more significant weight loss effects, with studies indicating a potential weight reduction of 15-22%. Saxenda’s weight loss effects are generally milder.
Dosing Frequency:
Mounjaro is injected once a week. Saxenda requires daily injections.
Suitable Candidates:
Mounjaro is mainly suitable for patients with a BMI ≥ 30 or BMI ≥ 27 with obesity-related diseases, particularly type 2 diabetes. Saxenda is suitable for patients with a BMI ≥ 30 or BMI ≥ 27 with obesity-related conditions (such as hypertension or diabetes).
Blood Sugar Control:
Mounjaro offers better blood sugar control for patients with type 2 diabetes.
Summary:
Both Mounjaro and Saxenda are effective weight loss medications, but Mounjaro may have advantages in weight loss effects and dosing frequency, especially for type 2 diabetes patients. However, the choice of medication should be based on individual circumstances and physician recommendations.
